BR112017011530A2 - polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação - Google Patents
polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilaçãoInfo
- Publication number
- BR112017011530A2 BR112017011530A2 BR112017011530A BR112017011530A BR112017011530A2 BR 112017011530 A2 BR112017011530 A2 BR 112017011530A2 BR 112017011530 A BR112017011530 A BR 112017011530A BR 112017011530 A BR112017011530 A BR 112017011530A BR 112017011530 A2 BR112017011530 A2 BR 112017011530A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptides
- amino acid
- acid sequence
- modified
- amyloid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
a invenção refere-se a polipeptídeos que compreendem uma porção do gene da proteína 3 de bacteriófago filamentoso (g3p) suficiente para se ligar a e/ou desagregar amiloide, por exemplo, a porção n1-n2 de g3p e seus mutantes e fragmentos, em que a se-quência de aminoácidos de g3p tenha sido modificada através da de-leção, inserção ou substituição de aminoácidos para remover um sinal de glicosilação putativo. a invenção se refere ainda a tais polipeptídeos que também são modificados através da substituição adicional de aminoácido para serem substancialmente menos imunogênicos do que a sequência de aminoácidos de g3p de tipo selvagem correspondente quando usada in vivo. os polipeptídeos da invenção retêm sua habilidade de se ligar e/ou desagregar o amiloide. a invenção ainda se refere ao uso desses polipeptídeos de g3p modificados no tratamento e/ou prevenção de doenças associadas com o erro de dobramento ou agregação do amiloide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462087052P | 2014-12-03 | 2014-12-03 | |
PCT/US2015/063476 WO2016090022A1 (en) | 2014-12-03 | 2015-12-02 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017011530A2 true BR112017011530A2 (pt) | 2018-03-13 |
Family
ID=55273507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017011530A BR112017011530A2 (pt) | 2014-12-03 | 2015-12-02 | polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação |
Country Status (20)
Country | Link |
---|---|
US (2) | US10722551B2 (pt) |
EP (1) | EP3227313B1 (pt) |
JP (2) | JP6730988B2 (pt) |
KR (1) | KR20170085132A (pt) |
CN (1) | CN107250154A (pt) |
AR (1) | AR102890A1 (pt) |
AU (1) | AU2015358504A1 (pt) |
BR (1) | BR112017011530A2 (pt) |
CA (1) | CA2969128A1 (pt) |
DK (1) | DK3227313T3 (pt) |
EA (1) | EA201791212A1 (pt) |
ES (1) | ES2910017T3 (pt) |
IL (1) | IL252426A0 (pt) |
MX (1) | MX2017007059A (pt) |
PH (1) | PH12017501004A1 (pt) |
PL (1) | PL3227313T3 (pt) |
PT (1) | PT3227313T (pt) |
SG (1) | SG11201704427YA (pt) |
TW (1) | TW201632542A (pt) |
WO (1) | WO2016090022A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA029602B1 (ru) | 2011-11-29 | 2018-04-30 | Проклара Байосайенсиз, Инк. | Применение белков р3 бактериофага в качестве агентов, связывающих амилоид |
PT2906235T (pt) | 2012-10-02 | 2017-09-28 | Proclara Biosciences Inc | Utilização de p3 de proteínas de fusão de bacteriófago como agentes ligantes amilóides |
KR20160010618A (ko) | 2013-05-28 | 2016-01-27 | 뉴로페이지 파마슈티컬즈, 인크. | 감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드 |
KR20170085132A (ko) | 2014-12-03 | 2017-07-21 | 프로클라라 바이오사이언시즈, 인크. | 글리코실화 신호가 결핍된 변형된 박테리오파지 g3p 아미노산 서열을 포함하는 폴리펩티드 |
JP2021527407A (ja) * | 2018-06-15 | 2021-10-14 | プロクララ バイオサイエンシーズ, インコーポレイテッド | 全般的アミロイド相互作用モチーフ(gaim) |
WO2024119183A1 (en) | 2022-12-02 | 2024-06-06 | Alzheon, Inc. | Methods for treating neurodegenerative disorders with tramiprosate |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
ATE236249T1 (de) | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | Tfn-bindende proteine |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
WO1992016221A1 (en) | 1991-03-15 | 1992-10-01 | Synergen, Inc. | Pegylation of polypeptides |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
ES2252732T3 (es) | 1992-05-26 | 2006-05-16 | Immunex Corporation | Nueva citoquina que une cd30. |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
ES2278463T3 (es) | 1998-12-08 | 2007-08-01 | Biovation Limited | Metodo para reducir la inmunogenicidad de proteinas. |
US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
RU2363707C2 (ru) | 2001-02-19 | 2009-08-10 | Мерк Патент Гмбх | Искусственные белки с пониженной иммуногенностью |
EP1366074B1 (en) | 2001-03-08 | 2006-09-13 | MERCK PATENT GmbH | Modified granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity |
DE10238846A1 (de) | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Aktive Fusionsproteine und Verfahren zu ihrer Herstellung |
DE602006020697D1 (de) | 2005-02-01 | 2011-04-28 | Univ Ramot | Verfahren zur behandlung von entzündungen in zusammenhang mit amyloid-ablagerungen und hirnhautentzündung unter beteiligung aktivierter mikroglia |
AU2007214399A1 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel-Aviv University | Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain |
EP1991259B1 (en) | 2006-02-15 | 2012-10-10 | Ramot at Tel-Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
EP2003200A4 (en) | 2006-04-06 | 2009-09-02 | Fumiaki Uchiyama | PHAGIC EXPRESSION BY A NEW FILAMENTOUS BACTERIOPHAGE |
WO2008011503A2 (en) | 2006-07-21 | 2008-01-24 | Ramot At Tel Aviv University Ltd. | Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates |
US20100017370A1 (en) | 2006-10-11 | 2010-01-21 | Antitope Limited | T cell epitope databases |
US20110182948A1 (en) | 2008-05-22 | 2011-07-28 | Beka Solomon | Method for treating disease characterized by plaque |
NZ592928A (en) | 2008-11-24 | 2012-12-21 | Univ Ramot | Method for treating parkinson' s disease using filamentous bacteriophage |
WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
BR112013023040A2 (pt) | 2011-03-11 | 2018-10-23 | Univ Ramot | bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa. |
EA029602B1 (ru) | 2011-11-29 | 2018-04-30 | Проклара Байосайенсиз, Инк. | Применение белков р3 бактериофага в качестве агентов, связывающих амилоид |
PT2906235T (pt) | 2012-10-02 | 2017-09-28 | Proclara Biosciences Inc | Utilização de p3 de proteínas de fusão de bacteriófago como agentes ligantes amilóides |
KR20160010618A (ko) * | 2013-05-28 | 2016-01-27 | 뉴로페이지 파마슈티컬즈, 인크. | 감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드 |
KR20170085132A (ko) | 2014-12-03 | 2017-07-21 | 프로클라라 바이오사이언시즈, 인크. | 글리코실화 신호가 결핍된 변형된 박테리오파지 g3p 아미노산 서열을 포함하는 폴리펩티드 |
-
2015
- 2015-12-02 KR KR1020177017763A patent/KR20170085132A/ko unknown
- 2015-12-02 WO PCT/US2015/063476 patent/WO2016090022A1/en active Application Filing
- 2015-12-02 SG SG11201704427YA patent/SG11201704427YA/en unknown
- 2015-12-02 DK DK15831011.0T patent/DK3227313T3/da active
- 2015-12-02 TW TW104140347A patent/TW201632542A/zh unknown
- 2015-12-02 CA CA2969128A patent/CA2969128A1/en not_active Abandoned
- 2015-12-02 ES ES15831011T patent/ES2910017T3/es active Active
- 2015-12-02 AU AU2015358504A patent/AU2015358504A1/en not_active Abandoned
- 2015-12-02 EP EP15831011.0A patent/EP3227313B1/en active Active
- 2015-12-02 EA EA201791212A patent/EA201791212A1/ru unknown
- 2015-12-02 BR BR112017011530A patent/BR112017011530A2/pt not_active Application Discontinuation
- 2015-12-02 US US15/532,820 patent/US10722551B2/en active Active
- 2015-12-02 MX MX2017007059A patent/MX2017007059A/es unknown
- 2015-12-02 CN CN201580065696.9A patent/CN107250154A/zh active Pending
- 2015-12-02 PL PL15831011T patent/PL3227313T3/pl unknown
- 2015-12-02 PT PT158310110T patent/PT3227313T/pt unknown
- 2015-12-02 JP JP2017529043A patent/JP6730988B2/ja active Active
- 2015-12-03 AR ARP150103956A patent/AR102890A1/es unknown
-
2017
- 2017-05-22 IL IL252426A patent/IL252426A0/en unknown
- 2017-05-31 PH PH12017501004A patent/PH12017501004A1/en unknown
-
2020
- 2020-02-19 JP JP2020026300A patent/JP2020073610A/ja not_active Withdrawn
- 2020-06-18 US US16/905,128 patent/US11723951B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10722551B2 (en) | 2020-07-28 |
CA2969128A1 (en) | 2016-06-09 |
PL3227313T3 (pl) | 2022-05-09 |
MX2017007059A (es) | 2018-05-02 |
EP3227313B1 (en) | 2022-02-09 |
PH12017501004A1 (en) | 2017-12-18 |
JP2020073610A (ja) | 2020-05-14 |
JP6730988B2 (ja) | 2020-07-29 |
AU2015358504A8 (en) | 2017-07-13 |
DK3227313T3 (da) | 2022-04-19 |
PT3227313T (pt) | 2022-04-12 |
US20180207231A1 (en) | 2018-07-26 |
TW201632542A (zh) | 2016-09-16 |
EP3227313A1 (en) | 2017-10-11 |
EA201791212A1 (ru) | 2018-01-31 |
US11723951B2 (en) | 2023-08-15 |
KR20170085132A (ko) | 2017-07-21 |
US20210015895A1 (en) | 2021-01-21 |
JP2017538407A (ja) | 2017-12-28 |
WO2016090022A9 (en) | 2016-08-25 |
AU2015358504A1 (en) | 2017-06-29 |
IL252426A0 (en) | 2017-07-31 |
WO2016090022A1 (en) | 2016-06-09 |
ES2910017T3 (es) | 2022-05-11 |
WO2016090022A8 (en) | 2017-06-22 |
SG11201704427YA (en) | 2017-06-29 |
CN107250154A (zh) | 2017-10-13 |
AR102890A1 (es) | 2017-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017011530A2 (pt) | polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação | |
BR112018072915A2 (pt) | peptídeo cíclico isolado e composição farmacêutica | |
BR112015032875A2 (pt) | derivados de peptídeos do tipo glp-1, e usos dos mesmos | |
WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
PH12015502585A1 (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity | |
AU2016240220B2 (en) | Designed ankyrin repeat domains with binding specificity for serum albumin | |
BR112016025297A2 (pt) | adenovírus que compreende uma porção de ligação a albumina | |
BR112015021414A2 (pt) | vírus da doença newcastle e seus usos | |
WO2016107818A8 (en) | Compositions and methods for protein glycosylation | |
CA2818969A1 (en) | Improved n-terminal capping modules for designed ankyrin repeat proteins | |
PH12021550992A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
BR112018071466A2 (pt) | novos peptídeos de ligação a cd1d imunogênicos | |
WO2014204816A3 (en) | Method for assessing protein identity and stability | |
BR112018074869A2 (pt) | anticorpos antagonistas que ligam t ao tgfb1, tgfb2 e ao tgfb3 humanos e seu uso para o tratamento de fibrose pulmonar | |
NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
BR112018006724A2 (pt) | ácido caurenoico hidroxilases | |
BR112016014069A2 (pt) | receptor de células t (tcr); ácido nucleico; célula não ocorrendo naturalmente e/ou purificada e/ou manipulada; composição farmacêutica; e tcr ou célula | |
BR112016016917A2 (pt) | Sistema de administração de fármaco | |
BR112019008237A2 (pt) | geranilgeranil pirofosfato sintases | |
WO2014145368A3 (en) | Modification and novel compositions of human secretoglobin proteins | |
BR112016030096A2 (pt) | composição imunogênica, vacina, uso de uma composição imunogênica ou de uma vacina, e, método para prevenção ou tratamento de uma doença. | |
SA518400176B1 (ar) | مستخلص من أوراق التبغ واستخدامه لعلاج إدمان التبغ | |
MX2022001489A (es) | Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d. | |
BR112016019002A2 (pt) | composições para a prevenção e/ou o tratamento de patologias associadas a alfa-glicosidase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |